Ian M. Catlett
Bristol-Myers Squibb (Sweden)(SE)Incyte (United States)(US)
Publications by Year
Research Areas
Cytokine Signaling Pathways and Interactions, Systemic Lupus Erythematosus Research, Monoclonal and Polyclonal Antibodies Research, Psoriasis: Treatment and Pathogenesis, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain(2019)272 cited
- → Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)*(2019)232 cited
- → Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial(2022)227 cited
- → Recruitment of CD40 and Tumor Necrosis Factor Receptor-associated Factors 2 and 3 to Membrane Microdomains during CD40 Signaling(2000)200 cited
- → Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab(2019)184 cited
- → Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors(2021)122 cited